
Non-factor Replacement Hemophilia Therapies
Adapted from: Global NMO Training 2018 plenary presentation by Glenn Pierce Reviewed by: Glenn Pierce Edited by: Georghia Michael The
Year: 2024
Language: English
Author(s): World Federation of Hemophilia
Format: Video
The World Federation of Hemophilia (WFH) Shared decision-making (SDM) tool helps clinicians and people with hemophilia work together to make treatment decisions based on clinical evidence that balances risks and expected outcomes with patient preferences and values.
Listen to three free 90-minute webinars covering the different hemophilia treatments and the applications of this important tool for healthcare practitioners and people with hemophilia.
Listen to this free 90-minute webinar covering the different aspects and applications of factor and non-factor hemophilia treatments, such as standard half-life (SHL), extended half-life (EHL), bispecific antibody, and rebalancing agent products, and gene therapy.
Speakers for the session will include Glenn Pierce, MD, PhD, Vice President, Medical, WFH; Barbara Konkle, MD, WFH Board Member; and Steven Pipe, MD. Participants will also have the opportunity to hear testimonials from people with hemophilia, Enrique Preza and Hazri Aris, who have made treatment changes.
Listen to this free 90-minute webinar on how to consider the benefits and risks of factor and non-factor treatments available for hemophilia.
Speakers for the session will include Glenn Pierce, MD, PhD, Vice President, Medical, WFH; Barbara Konkle, MD, WFH Board Member; and Steven Pipe, MD. Participants will have the opportunity to hear testimonials from people with hemophilia, Garrett Hayes and Jay Konduros, who have made treatment changes.
Listen to this free 90-minute webinar on the advantages of using shared decision-making for people with hemophilia and for healthcare providers, including real-life experiences of HCP and PWH using the WFH SDM Tool.
Speakers for the session will include Donna Coffin, Sara Garcia Barcenilla and Mariette Driessens. Presentations were followed by a panel discussion, with insight from Glenn Pierce, MD, PhD, Barbara Konkle, MD, Hazri Aris, Jay Konduros, Garrett Hayes and Enrique Preza.
The WFH does not engage in the practice of medicine and under no circumstances recommends particular treatment for specific individuals. For diagnosis or consultation on a specific medical problem, the WFH recommends that you contact your physician or local treatment centre. Before administering any products, the WFH urges patients to check dosages with a physician or hemophilia centre staff, and to consult the pharmaceutical company’s printed instructions.
The WFH does not promote any particular pharmaceutical product and any mention of any commercial brand in this presentation is strictly for educational purposes.

Adapted from: Global NMO Training 2018 plenary presentation by Glenn Pierce Reviewed by: Glenn Pierce Edited by: Georghia Michael The

Adapted from: Global NMO Training 2016 plenary presentation by Glenn Pierce Reviewed by: Glenn Pierce Edited by: Georghia Michael This

In the Monday morning session entitled Inhibitors: Clinical Aspects, Henry Daniell presents current advances in the development of new, affordable

The purpose of this guide is to inform and facilitate the selection and purchase of therapeutic products for the treatment

A summary of discussions held at the Tenth WFH Global Forum on Research and Treatment Products for Bleeding Disorders which

This illustrated schematic demonstrates the normal process of blood clotting, how it is diminished when a clotting factor is lacking,